このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

有害事象、疾患活動性の変化、中等度から重度の活動性クローン病を患う小児参加者の体内でリサンキズマブの静脈内および皮下投与がどのように移行するかを評価する研究 (RISE)

2026年10月15日 更新者:AbbVie

小児対象(2歳以上18歳未満)を対象に、非盲検導入、ランダム化二重盲検維持、および長期延長期間を用いてリサンキズマブの薬物動態、有効性、安全性を評価する第3相多施設共同研究中等度から重度の活動性クローン病

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to < 18 years old who have had intolerance or inadequate response to other therapies.

Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is being developed for the treatment of CD in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 years. Cohort 2 will enroll participants with ages from 2 to less than 6 years. Cohort 3 will enroll participants with ages from 2 to less than 18 years. SS1 is an open-label induction period where participants will receive a weight-based induction regimen of risankizumab. SS2 is a double-blind maintenance period where participants will be randomized to receive 1 of 2 doses of weight-based induction regimen of risankizumab. SS3 is an open-label extension period where participants will receive risankizumab based off of their response in SS2. Approximately 110 pediatric participants with CD will be enrolled at around 100 sites worldwide.

Participants in SS1 will receive risankizumab intravenously during the 12-week induction period. Participants in SS2 will receive risankizumab subcutaneously during the 52-week randomized maintenance period. Participants in SS3 will receive risankizumab subcutaneously during the 208-week open label period. Participants will be followed-up for approximately 140 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

調査の概要

状態

募集

研究の種類

介入

入学 (推定)

110

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85016-7710
        • 募集
        • Phoenix Children's Hospital /ID# 255766
    • Arkansas
      • Little Rock、Arkansas、アメリカ、72202
        • 完了
        • Arkansas Children's Hospital /ID# 255762
    • California
      • Oakland、California、アメリカ、94609
        • 募集
        • UCSF Benioff Children's Hospital - Oakland /ID# 258327
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • 募集
        • Children's Hospital Colorado - Aurora /ID# 255764
    • Florida
      • Orlando、Florida、アメリカ、32806-1141
        • 募集
        • Arnold Palmer Hospital for Children Center Digestive Health and Nutrition-Orland /ID# 255437
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • 募集
        • Indiana University Health Riley Hospital for Children /ID# 256454
    • Massachusetts
      • Waltham、Massachusetts、アメリカ、02451
        • 募集
        • Massachusetts General Hospital - Mass General Waltham /ID# 255767
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55413-2195
        • 募集
        • MNGI Digestive Health, P. A. /ID# 255366
    • New Jersey
      • Morristown、New Jersey、アメリカ、07960
        • 募集
        • Goryeb Childrens Hospital /ID# 256452
    • New York
      • New York、New York、アメリカ、10029
        • 募集
        • Icahn School of Medicine at Mount Sinai /ID# 254880
    • Ohio
      • Cleveland、Ohio、アメリカ、44195
        • 募集
        • Cleveland Clinic - Cleveland /ID# 256453
        • コンタクト:
          • Site Coordinator
          • 電話番号:216-636-2007
      • Birmingham、イギリス、B4 6NH
        • 募集
        • Birmingham Women's and Children's NHS Foundation Trust /ID# 255759
    • England
      • Sheffield、England、イギリス、S10 2TH
        • 募集
        • Sheffield Children's Hospital NHS Foundation Trust /ID# 255758
        • コンタクト:
          • Site Coordinator
          • 電話番号:+44 114 273 0522
    • Greater London
      • London、Greater London、イギリス、E1 2ES
        • 募集
        • Disc_Barts Health NHS Trust - The Royal London Hospital /ID# 255757
    • Central District
      • Petah Tikva、Central District、イスラエル、4920235
        • 募集
        • Schneider Children's Medical Center /ID# 254950
    • Jerusalem
      • Jerusalem、Jerusalem、イスラエル、91031
        • 募集
        • Shaare Zedek Medical Center /ID# 254951
      • Messina、イタリア、98125
        • 募集
        • Azienda Ospedaliera Universitaria Gaetano Martino /ID# 255044
    • Genova
      • Genoa、Genova、イタリア、16147
        • 募集
        • IRCCS Istituto Giannina Gaslini /ID# 255262
    • Napoli
      • Naples、Napoli、イタリア、80131
        • 募集
        • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 255045
    • Roma
      • Rome、Roma、イタリア、00165
        • 募集
        • Ospedale Pediatrico Bambino Gesu /ID# 255043
    • North Holland
      • Amsterdam、North Holland、オランダ、1105 AZ
        • 募集
        • Amsterdam University Medical Center /ID# 254827
    • Alberta
      • Calgary、Alberta、カナダ、T3B 6A8
        • 募集
        • Alberta Children's Hospital /ID# 255357
      • Edmonton、Alberta、カナダ、T6G 1C9
        • 募集
        • Edmonton Clinic Health Academy /ID# 255361
    • British Columbia
      • Vancouver、British Columbia、カナダ、V6H 3V4
        • 募集
        • BC Children's Hospital /ID# 255359
    • Ontario
      • London、Ontario、カナダ、N6A 5W9
        • 募集
        • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 258598
      • Bern、スイス、3010
        • 募集
        • Inselspital, Universitaetsspital Bern /ID# 255321
    • Canton of Zurich
      • Zurich、Canton of Zurich、スイス、8032
        • 募集
        • Kinderspital Zurich - Eleonorenstiftung /ID# 255337
    • Stockholm County
      • Stockholm、Stockholm County、スウェーデン、118 83
        • 募集
        • Sodersjukhuset /ID# 255239
      • Stockholm、Stockholm County、スウェーデン、171 76
        • 募集
        • Astrid Lindgrens Barnsjukhus /ID# 255240
    • Västra Götaland County
      • Gothenburg、Västra Götaland County、スウェーデン、413 46
        • 募集
        • Sahlgrenska Universitetssjukhuset /ID# 255236
        • コンタクト:
          • Site Coordinator
          • 電話番号:+46313435865
      • Madrid、スペイン、28009
        • 完了
        • Hospital Infantil Universitario Nino Jesus /ID# 255012
      • Málaga、スペイン、29011
        • 募集
        • Hospital Regional Universitario de Malaga /ID# 257553
    • A Coruna
      • Ferrol、A Coruna、スペイン、15405
        • 募集
        • Hospital Arquitecto Marcide - Complejo Hospitalario Universitario de Ferrol /ID# 255614
    • Praha 17
      • Prague、Praha 17、チェコ、128 00
        • 完了
        • Vseobecna Fakultni nemocnice v Praze /ID# 256096
    • Praha 5
      • Prague、Praha 5、チェコ、150 06
        • 完了
        • Fakultni nemocnice Motol a Homolka /ID# 256547
      • Ankara、トルコ(Türkiye)、06560
        • 募集
        • Gazi University Medical Faculty /ID# 255086
      • Istanbul、トルコ(Türkiye)、34453
        • 募集
        • Sariyer Hamidiye Etfal Egitim Ve Araştirma Hastanesi /ID# 257143
      • Istanbul、トルコ(Türkiye)、34899
        • 募集
        • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 261020
      • Kocaeli、トルコ(Türkiye)、41380
        • 募集
        • Kocaeli University Med Faculty /ID# 256922
    • Bavaria
      • Munich、Bavaria、ドイツ、80337
        • 募集
        • Dr. von Haunerschen Kinderspital /ID# 255577
    • North Rhine-Westphalia
      • Münster、North Rhine-Westphalia、ドイツ、48149
        • 募集
        • Universitaetsklinikum Muenster /ID# 256762
      • Paris、フランス、75015
        • 募集
        • AP-HP - Hopital Necker /ID# 255608
    • Centre-Val de Loire
      • Tours、Centre-Val de Loire、フランス、37044
        • 募集
        • CHRU Tours - Hopital Gatien de Clocheville /ID# 255052
    • New Aquitaine
      • Bordeaux、New Aquitaine、フランス、33076
        • 募集
        • Chu Bordeaux - Hopital Pellegrin /ID# 257060
    • Occitanie
      • Toulouse、Occitanie、フランス、31059
        • 募集
        • CHU Toulouse - Hopital Paule de Viguier /ID# 255609
    • Rhone
      • Bron、Rhone、フランス、69500
        • 募集
        • Hospices Civils de Lyon - Hopital Femme Mere Enfant /ID# 255443
      • Plovdiv、ブルガリア、4002
        • 募集
        • UMHAT Sveti Georgi EAD /ID# 255386
      • Sofia、ブルガリア、1606
        • 完了
        • Specialized Hospital For Active Treatment Of Children Diseases Prof. Ivan Mitev /ID# 255384
      • Varna、ブルガリア、9009
        • 募集
        • UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 256358
      • Dorado、プエルトリコ、00646
        • 募集
        • Puerto Rico Health Institute /ID# 255071
      • San Juan、プエルトリコ、00909-1711
        • 募集
        • Clinical Research Puerto Rico /ID# 266479
      • Brussels、ベルギー、1020
        • 募集
        • Hospital Universite Enfants Reine Fabiola /ID# 255112
      • Liège、ベルギー、4000
        • 募集
        • Groupe Sante CHC - Clinique du MontLegia /ID# 255620
    • Antwerpen
      • Edegem、Antwerpen、ベルギー、2650
        • 募集
        • Uza /Id# 255114
    • Brussels Capital
      • Brussels、Brussels Capital、ベルギー、1200
        • 募集
        • Cliniques Universitaires UCL Saint-Luc /ID# 255108
      • Jette、Brussels Capital、ベルギー、1090
        • 募集
        • Universitair Ziekenhuis Brussel /ID# 255109
    • Vlaams-Brabant
      • Leuven、Vlaams-Brabant、ベルギー、3000
        • 募集
        • Universitair Ziekenhuis Leuven /ID# 255098
    • Kuyavian-Pomeranian Voivodeship
      • Torun、Kuyavian-Pomeranian Voivodeship、ポーランド、87-100
        • 完了
        • Gastromed Sp. z o.o /ID# 255939
    • Masovian Voivodeship
      • Warsaw、Masovian Voivodeship、ポーランド、04-730
        • 募集
        • Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 255938
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100045
        • 募集
        • Beijing Children's Hospital /ID# 256081
      • Beijing、Beijing Municipality、中国、100191
        • 募集
        • Peking University Third Hospital /ID# 255876
        • コンタクト:
          • Site Coordinator
          • 電話番号:+86 010-82266699
    • Guangdong
      • Guangzhou、Guangdong、中国、510620
        • 募集
        • Guangzhou Medical University Affiliated Women and Children's Medical Center /ID# 255428
      • Guangzhou、Guangdong、中国、510655
        • 募集
        • The Sixth Affiliated Hospital of Sun Yat-sen University /ID# 270589
    • Henan
      • Zhengzhou、Henan、中国、450018
        • 募集
        • Henan Children's Hospital Zhengzhou Children's Hospital /ID# 255562
    • Hunan
      • Changsha、Hunan、中国、410007
        • 募集
        • Hunan Children's Hospital /ID# 255610
    • Jiangxi
      • Nanchang、Jiangxi、中国、330006
        • 募集
        • Jiangxi Provincial Children's Hospital /ID# 255564
    • Liaoning
      • Shenyang、Liaoning、中国、110022
        • 募集
        • Shengjing Hospital of China Medical University /ID# 255563
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200062
        • 募集
        • Children's Hospital of Shanghai /ID# 255531
      • Shanghai、Shanghai Municipality、中国、200065
        • 募集
        • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 255688
      • Changhua City, Changhua County、台湾、50006
        • 募集
        • Changhua Christian Hospital /ID# 256082
      • Taipei、台湾、100
        • 募集
        • National Taiwan University Hospital /ID# 255679
    • Aichi-ken
      • Ōbu、Aichi-ken、日本、474-8710
        • 募集
        • Aichi Children's Health And Medical Center /ID# 272085
    • Chiba
      • Kashiwa-shi、Chiba、日本、277-0871
        • 募集
        • Tsujinaka Hospital - Kashiwanoha /ID# 268409
    • Fukuoka
      • Kurume-shi、Fukuoka、日本、830-0011
        • 募集
        • Kurume University Hospital /ID# 268418
    • Gunma
      • Maebashi、Gunma、日本、371-8511
        • 募集
        • Gunma University Hospital /ID# 270560
    • Kumamoto
      • Kumamoto、Kumamoto、日本、861-8520
        • 募集
        • Japanese Red Cross Kumamoto Hospital /ID# 268586
    • Osaka
      • Izumi-Shi、Osaka、日本、594-1101
        • 募集
        • Osaka Women's and Children's Hospital /ID# 268419
    • Saitama
      • Saitama-shi、Saitama、日本、330-8777
        • 募集
        • Saitama Children's Medical Center /ID# 268410
    • Tokyo
      • Bunkyo-ku、Tokyo、日本、113-8519
        • 募集
        • Institute of Science Tokyo Hospital /ID# 269175
      • Fuchu-shi、Tokyo、日本、183-8561
        • 募集
        • Tokyo Metropolitan Children's Medical Center /ID# 268415
      • Setagaya City、Tokyo、日本、157-8535
        • 募集
        • National Center For Child Health And Development /ID# 268420
      • Daegu、韓国、41404
        • 募集
        • Kyungpook National University Chilgok Hospital /ID# 255817
    • Seoul Teugbyeolsi
      • Seoul、Seoul Teugbyeolsi、韓国、03080
        • 募集
        • Seoul National University Hospital /ID# 255318
      • Seoul、Seoul Teugbyeolsi、韓国、06351
        • 募集
        • Samsung Medical Center /ID# 255284
      • Seoul、Seoul Teugbyeolsi、韓国、03722
        • 募集
        • Yonsei University Health System - Severance Hospital /ID# 256976

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

2年~17年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Pediatric individuals, 2 to < 18 years old
  • Must have moderately to severely active CD, as defined by the PCDAI score > 30 assessed at Baseline
  • Must have endoscopic evidence of mucosal inflammation as documented by the SES-CD of ≥ 6 for ileocolonic or colonic disease (or SES-CD of ≥ 4 for isolated ileal disease)
  • Demonstrated intolerance or inadequate response to one or more of the following categories of drugs: aminosalicylates (This drug class is not sufficient for eligibility for subjects in France, Italy, Netherlands, Spain, and Sweden), oral locally acting corticosteroids, systemic steroids (prednisone or equivalent), IMMs, and/or biologic therapies

Exclusion Criteria:

  • History of hereditary fructose intolerance (a rare genetic condition) or an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class

  • Any of the following medical disorders:

    1. Current diagnosis of ulcerative colitis, indeterminate colitis, or monogenic IBD.

    2. A diagnosis of CD prior to 2 years of age.

    3. A diagnosis or suspected diagnosis of a primary immunodeficiency.

    4. Currently known complications of CD such as:

      • Active abscess (abdominal or perianal);
      • Symptomatic bowel strictures;
      • > 2 missing segments of the following 5 segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum;
      • Fulminant colitis;
      • Toxic megacolon;
      • Or any other manifestation that might require surgery while enrolled in the study.
    5. Ostomy or ileoanal pouch.

    6. Diagnosis of short gut or short bowel syndrome.

    7. Surgical bowel resection within the past 3 months prior to Baseline (excluding gastrointestinal surgeries which are not bowel resections such as appendectomy or ostomy closure), or a history of >3 bowel resections.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:PK Cohort 1: SS3 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:PK Cohort 1: SS3 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:PK Cohort 2: SS1

Cohort 2 will enroll participants aged 2 to less than 6 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:PK Cohort 2: SS3 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:PK Cohort 2: SS3 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:Expansion Cohort 3: SS3 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:Expansion Cohort 3: SS3 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. SS3 is a 208-week extension period where participants receive risankizumab based on their response in SS2.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:PK Cohort 1: SS1

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All participants who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:PK Cohort 1: SS2 Dose A

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:PK Cohort 1: SS2 Dose B

Cohort 1 will consist of 2 age groups (6 to < 12 years and 12 to < 18 years). Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:PK Cohort 2: SS2 Dose A

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:PK Cohort 2: SS2 Dose B

Cohort 2 will enroll participants aged 2 to less than 6 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:Expansion Cohort 3: SS1

Cohort 3 will enroll participants aged 2 to less than 18 years. SS1 is a 12-week induction period where participants will receive a weight-based dose of risankizumab. All subjects who complete SS1 are eligible to enter SS2.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:Expansion Cohort 3: SS2 Dose A

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose A. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ
実験的:Expansion Cohort 3: SS2 Dose B

Cohort 3 will enroll participants aged 2 to less than 18 years. Participants who complete SS1 will be randomized into a 52-week maintenance phase (SS2) to receive either double-blind risankizumab Dose B. Participants who complete SS2 will have the opportunity to enter the open-label long-term-extension SS3.

Intravenous (IV) Infusion

他の名前:
  • ABBV-066
  • スキリージ

Subcutaneous (SC) Injection

他の名前:
  • ABBV-066
  • スキリージ

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Cohort 3 (Substudy 2): Percentage of Participants Achieving Pediatric Crohn's Disease Activity Index (PCDAI) Clinical Remission
時間枠:At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per Simple Endoscopic Score for Crohn's Disease (SES-CD)
時間枠:At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2: Maximum Observed Serum Concentration (Cmax) of Risankizumab
時間枠:Up to approximately Week 64

Cmax of risankizumab

Up to approximately Week 64
Cohorts 1 & 2: Time to Cmax (Tmax) of Risankizumab
時間枠:Up to approximately 64 weeks

Tmax of risankizumab

Up to approximately 64 weeks
Cohorts 1 & 2: Area Under the Serum Concentration-Time Curve Over the Dosing Interval (AUCtau) of Risankizumab
時間枠:Up to approximately 64 weeks

AUCtau of risankizumab

Up to approximately 64 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Cohort 3 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
時間枠:At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
時間枠:At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohort 3 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
時間枠:At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
時間枠:At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohort 3 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
時間枠:At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving PCDAI Clinical Remission
時間枠:At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Response per SES-CD
時間枠:At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 64 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving PCDAI Clinical Remission
時間枠:At 12 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. Clinical remission was defined as PCDAI ≤ 10.

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Response per SES-CD
時間枠:At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic response is defined as a decrease in SES-CD > 50% from Baseline (or for participants with isolated ileal disease and a Baseline SES-CD of 4, at least a 2-point reduction from Baseline).

At 12 weeks
Cohorts 1 & 2 (Substudy 1): Percentage of Participants Achieving Endoscopic Remission per SES-CD
時間枠:At 12 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 12 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Endoscopic Remission per SES-CD
時間枠:At 64 weeks

The SES-CD assesses endoscopic disease severity by evidence of active intestinal mucosal inflammation. Endoscopic remission is defined as SES-CD ≤ 4 with at least a 2-point reduction from Baseline and no sub-score > 1, as scored by a central reader.

At 64 weeks
Cohorts 1 & 2 (Substudy 2): Percentage of Participants Achieving Corticosteroid-Free Clinical Remission per PCDAI
時間枠:At 64 weeks

PCDAI is an index used to measure disease activity of pediatric patients with Crohn's disease assessing abdominal pain, stool frequency, patient functioning, hematocrit, erythrocyte sedimentation rate, albumin, weight, height, abdomen, perirectal disease, and extraintestinal manifestations. It ranges from 0 to 100; higher scores indicate more active disease. PCDAI corticosteroid-free remission was defined as discontinued corticosteroid use at least 90 consecutive days prior to the respective visit, with a PCDAI ≤ 10 at that visit.

At 64 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:ABBVIE INC.、AbbVie

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年12月11日

一次修了 (推定)

2029年4月1日

研究の完了 (推定)

2029年4月1日

試験登録日

最初に提出

2023年8月10日

QC基準を満たした最初の提出物

2023年8月10日

最初の投稿 (実際)

2023年8月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月20日

QC基準を満たした最後の更新が送信されました

2026年10月15日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • M16-194
  • 2022-502050-14-00 (その他の識別子:EU CT)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD 共有時間枠

For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

IPD 共有アクセス基準

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する